Trial Profile

A Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Status: Suspended

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lazucirnon (Primary)
Indications Diabetic retinopathy
Focus Therapeutic Use
Sponsors Alkahest

Most Recent Events

26 Jan 2022 Planned End Date changed from 1 Oct 2022 to 1 Jul 2022.
26 Jan 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Feb 2022.
26 Jan 2022 Status changed from recruiting to suspended (Study suspended due to safety findings which require further analysis before dosing additional participants).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com